Investor Presentation Q1 2018

Investor Presentation First three months of 2018 Novo Nordisk is now the market leader in the USA within the modern and new-generation insulin segment Slide 45 - Novo Nordisk Modern insulin and new-generation insulin volume market shares in the USA Sanofi Eli Lilly USA insulin market by segment Device penetration Modern Insulin penetration tMU Penetration CAGR volume¹: 2.6% 160 100% 60% CAGR value¹: 21.2% 140 50% 80% 120 Fast-acting 40% 100 60% 80 Premix 30% 40% 60 20% 40 Long-acting 20% 10% 20 0 0% 0% Feb 2013 Feb Feb 2018 2013 1 CAGR for 5-year period Source: IQVIA monthly MAT Feb, 2018 volume and value (DKK) figures changing diabetes Source: IQVIA monthly MAT Feb, 2018 volume figures 40% 36% 24% Feb 2018 novo nordisk

View entire presentation